public KRASStandardReflexResult(string reportNo, Business.Test.AccessionOrder accessionOrder)
{
this.m_AccessionOrder = accessionOrder;
this.m_KRASStandardReflexTest = new KRASStandardReflexTest();
this.m_KRASStandardReflexTestOrder = (YellowstonePathology.Business.Test.KRASStandardReflex.KRASStandardReflexTestOrder) this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(reportNo);
this.m_KRASStandardTest = new KRASStandard.KRASStandardTest();
this.m_KRASStandardTestOrder = (YellowstonePathology.Business.Test.KRASStandard.KRASStandardTestOrder) this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(this.m_KRASStandardTest.PanelSetId, this.m_KRASStandardReflexTestOrder.OrderedOnId, true);
this.m_BRAFV600EKTest = new BRAFV600EK.BRAFV600EKTest();
this.m_BRAFV600EKTestOrder = (YellowstonePathology.Business.Test.BRAFV600EK.BRAFV600EKTestOrder) this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(this.m_BRAFV600EKTest.PanelSetId, this.m_KRASStandardReflexTestOrder.OrderedOn, true);
this.m_References = "1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626-1634. " +
"2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67(6): 2643-2648.";
}
public KRASStandardReflexResult(string reportNo, Business.Test.AccessionOrder accessionOrder)
{
this.m_AccessionOrder = accessionOrder;
this.m_KRASStandardReflexTest = new KRASStandardReflexTest();
this.m_KRASStandardReflexTestOrder = (YellowstonePathology.Business.Test.KRASStandardReflex.KRASStandardReflexTestOrder)this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(reportNo);
this.m_KRASStandardTest = new KRASStandard.KRASStandardTest();
this.m_KRASStandardTestOrder = (YellowstonePathology.Business.Test.KRASStandard.KRASStandardTestOrder)this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(this.m_KRASStandardTest.PanelSetId, this.m_KRASStandardReflexTestOrder.OrderedOnId, true);
this.m_BRAFV600EKTest = new BRAFV600EK.BRAFV600EKTest();
this.m_BRAFV600EKTestOrder = (YellowstonePathology.Business.Test.BRAFV600EK.BRAFV600EKTestOrder)this.m_AccessionOrder.PanelSetOrderCollection.GetPanelSetOrder(this.m_BRAFV600EKTest.PanelSetId, this.m_KRASStandardReflexTestOrder.OrderedOn, true);
this.m_References = "1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626-1634. " +
"2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67(6): 2643-2648.";
}